tbuckley/cabot-search huggingface dataset:
EXTH-07. TUMOR-TREATING-FIELD (TTFIELD) EFFECTS ON GLIOBLASTOMA CELLS ARE AUGMENTED BY MITOTIC CHECKPOINT INHIBITION
Authors: Almuth F. Kessler, Greta Eliza Frömbling
Journal: Neuro-Oncology (2016)

Tumor-treating-fields (TTFields) in addition to the standard therapy regimen have led to a significant increase in progression free and overall survival of glioblastoma (GBM) patients. TTFields are low intensity, alternating electric fields within the intermediate frequency range, disrupting cell division through inhibition of spindle-fiber formation. Likewise, the chemotherapeutic agent Vincristine inhibits spindle-fiber formation but, in contrast to TTFields, is associated with severe side effects. The spindle assembly checkpoint (SAC) diminishes therapeutic effects of spindle-damaging agents by monitoring the correct segregation of sister-chromatids. Inhibiting its key regulator monopolar spindle 1 (MPS1) has a synergistic effect together with Vincristine on GBM growth in mice. Therefore, MPS1-inhibition also may increase the efficacy of TTFields. The GBM cell line U87 was treated with TTFields using the Novocure inovitro™ laboratory research system for 72 hours alone and in combination with the MPS1 inhibitor MPS1-IN-3 (IN3). The combination of TTFields with MPS1-inhibition (TTFields + IN3) resulted in a decrease of GBM cell number by 47.5% compared to TTFields monotherapy (P = 0.0226), and by 72% compared to sole MPS1-inhibition (P = 0.0007). Nearly 4 times less cells were able to re-enter the G1 phase in the TTFields + IN3 group compared to TTFields alone (P = 0.0011), as determined by FACS-analysis. TUNEL assays revealed significantly more apoptotic cells appearing in the TTFields + IN3 group (6x increase vs. IN3, P = 0.0343; 8x increase vs. TTFields, P = 0.049). In addition, massive aberrant mitotic figures were visible in the TTFields treatment groups, detected by immunofluorescence microscopy. TTFields are already a promising, well tolerated new treatment modality on top of the standard treatment regimen. A combination of physically damaging the spindle apparatus by TTFields and chemical inhibition of the SAC may additionally augment TTFields efficacy.
Reduced Intensity (RI) Allogeneic Stem Cell Transplantation (ALLOSCT) with Umbilical Cord Blood (UCB) in Pediatric Patients with Malignant and Non-Malignant Diseases.
Authors: Mary Brigid Bradley, Lauren Harrison, Genia Billote, Erin Cooney, Gerard Reddy, Olga Militano, Karen Wolownik, Ria Hawks, Diane George, Gustavo Del Toro, James Garvin, Monica Bhatia, Prakash Satwani, Mitchell S. Cairo
Journal: Blood (2004)
Molecular characterization of PDL1 status of circulating tumor cells (CTCs) isolated with a novel label-free inertial microfluidic system from patients (pts) with advanced cancers
Authors: J. Fraser-Fish, Z. Ahmad, R. Kumar, B. Ebbs, G. Fowler, P. Flohr, M. Crespo, M. Ahmed, S. Popat, J. Bhosle, U. Banerji, M. O'Brien, J.S. de Bono, T.A. Yap
Journal: Annals of Oncology (2016)
CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients
Authors: L. Orgiano, F. Bruder, C. Madeddu, R. Marconcini, E. Gambale, E. Galizia, S. Stucci, F. Spagnolo, L. Di Guardo, C. Loi, F. Pani, D. Massa, E. Massa, G. Astara, M. Del Vecchio, F. Silvestris, M. de tursi, A. Falcone, P. Queirolo, M. Scartozzi
Journal: Annals of Oncology (2016)
A two-group study to evaluate the impact of an educational handbook in the care of patients with head and neck cancer (HNC).
Authors: Jessica Ruth Bauman, Areej El-Jawahri, Karen Quinn, Lisa Arcikowski, Gina Chan, Elene Viscosi, Carol Doherty, John Ross Clark, Jennifer S. Temel, Lori J. Wirth
Journal: Journal of Clinical Oncology (2016)

228 Background: Patients undergoing chemoradiotherapy for HNC have a significant symptom burden, psychological distress, and educational needs. We evaluated the impact of an educational handbook integrated into oncology care on patient outcomes. Methods: We conducted a two group, prospective, longitudinal study. Patients enrolled in group 1 received standard care as a control. Then, patients in group 2 received the intervention of a specialized handbook integrated into weekly visits with oncology clinicians during treatment. To assess preliminary efficacy, we evaluated satisfaction (Information Satisfaction Questionnaire-ISQ), mood (Hospital Anxiety and Depression Scale-HADS), illness perception (Brief Illness Perception Questionnaire-IPQ), and quality of life (QOL) (MD Anderson Symptom Inventory-Head and Neck-MDASI-HN) at baseline and week 3. We compared outcomes using two sample t-tests and measured effect size using Cohen’s D. Results: From 8/2014-5/2015 we enrolled and followed 30 patients in group 1. From 5/2015-12/2015, we enrolled and followed 30 patients in group 2. There were no significant differences in baseline characteristics. There were more missing data from group 2. There were high levels of satisfaction in both groups. 20/23 (87%) reported they would ‘definitely’ recommend the handbook to others. Changes in outcomes are shown in Table 1. Compared to group 1, group 2 reported a less threatening view of illness, lower better symptom burden, and less anxiety, but these were not statistically significant. Conclusions: The specialized handbook for patients with HNC was well received. The sample size was too small to detect differences in mood, QOL, illness perception, or satisfaction. Further development in a larger cohort is warranted. Clinical trial information: NCT02204631. [Table: see text]
E-cigarettes users have lower carcinogen and toxin levels than smokers, study finds
Authors: Susan Mayor
Journal: BMJ (2017)

Former smokers who have completely replaced standard cigarettes with e-cigarettes show substantial reductions in levels of tobacco related carcinogens and toxins compared with those who continue to smoke cigarettes, a study has found.1

The study, funded by Cancer Research UK, compared biomarkers for nicotine, tobacco related carcinogens, and toxins in five purposively recruited: people smoking only standard cigarettes; former smokers using only e-cigarettes for at least six months; former smokers using only nicotine replacement therapy (NRT); people using both standard cigarettes and e-cigarettes; people using both standard cigarettes and …
Results of a phase Ib study of Q-122 treatment of vasomotor symptoms in breast cancer patients.
Authors: Wendy Painter, April L. Speed, Kiwita Phillips, Priscilla Pemu, Alice Robertson, Earl Sands, Elizabeth Ofili
Journal: Journal of Clinical Oncology (2015)

99 Background: Breast cancer patients taking tamoxifen (TAM) or an aromatase inhibitor (AI) often develop severe vasomotor symptoms (VMS) yet the only FDA approved non-hormonal treatment for VMS, 7.5 mg paroxetine, has a warning against concomitant use with TAM. Q-122, an orally-available small molecule, is being developed to address this unmet medical need. Results from the Phase 1b study, Q-1001, are presented. Methods: Q-1001 was a Phase 1 open-label, two-dose, dose-escalation study of the safety and preliminary effectiveness of Q-122 in females with breast cancer currently taking TAM or an AI and experiencing an average of at least 7-8 moderate to severe hot flashes per day. Key exclusion criteria included significant renal or hepatic disease, untreated hyperthyroidism and clinically significant abnormal laboratory findings. The study period included a 2 week drug-free screening phase, 28 day treatment phase, and 2 week drug-free follow-up period. Subjects were initially enrolled into Group 1 (100 mg Q-122) followed by Group 2 (200 mg Q-122). Safety was assessed by review of adverse events (AEs), physical findings and laboratory values. The primary efficacy endpoints were mean changes in frequency and severity (hot flash severity score, HFSS) of moderate and severe hot flashes from baseline to Week 4. Menopausal symptoms were assessed using the Greene Climacteric Scale (GCS). Results: 10 and 11 subjects received 100 and 200 mg Q-122 respectively; 8 subjects in each group completed the study. At the end of treatment for groups 1 and 2 respectively, the daily average frequency of hot flashes was reduced from 9.9 to 4.1 and from 8.6 to 3.2, and the mean HFSS was reduced by 62% and 68% from baseline values. Menopausal symptoms assessed using the GCS were significantly reduced from baseline (psychological: -82%; somatic: -65%; vasomotor: -65%). All AEs (n = 29) were either mild (79%) or moderate (21%) in severity and only 3 (all in one subject) were considered possibly related to study drug. Conclusions: Treatment with Q-122 resulted in significant reduction in the frequency and severity of VMS and improvement in menopausal symptoms as assessed by the GCS. No safety issues associated with the use of Q-122 were identified in this study.
EMBARK: A phase 3, randomized, efficacy and safety study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy
Authors: K. Miller, P. Mulders, S.J. Freedland, H. Scher, N. Shore, E. Park, A. Krivoshik, D. Phung, K. Modelska, P. Scardino
Journal: Annals of Oncology (2016)
Tracking emerging KRAS and BRAF mutations through ccfDNA in colorectal cancers treated with EGFR blockade
Authors: T. Yamada, G. Takahashi, T. Iwai, K. Takeda, M. Koizumi, S. Shinji, Y. Yokoyama, K. Hara, M. Hotta, A. Matsuda, S. Matsumoto, K. Ohta, E. Uchida
Journal: Annals of Oncology (2016)
ATIM-34. RATES AND OUTCOMES OF COMBINATION TUMOR TREATING FIELDS AND IMMUNOTHERAPY IN A GLIOMA COHORT
Authors: Yazman Odia, Laura Donovan, Jessica Schulte, Fabio Iwamoto
Journal: Neuro-Oncology (2016)

Tumor-treating fields (TTF) are approved for use in patients with glioblastomas at recurrence (2011) or adjuvant setting (2016) due to survival benefit in various trials. Since 12/2012, 46 patients were treated with Optune for de novo or recurrent gliomas at Columbia University. Rates and outcomes when used concurrently with immunotherapy were analyzed, given the recent preclinical data of synergism between TTF and PD1 targeted therapy. Of 46 treated patients, 18 (39%) were women and 2 (4%), 4 (9%) and 40 (87%) had WHO grade II, III and IV gliomas. Median age at diagnosis was 56 (23-84) years. TTF was used at recurrence in 35 [76%, median 2 (0-4) prior recurrences] or at diagnosis in 11 (24%). Prior bevacizumab therapy was used in 18 (39%) in addition to surgery, radiation and temozolomide. Median time to TTF initiation was 15 months, ranging 2.8 months to 17 years, from diagnosis. Median TTF therapy duration was 1.6 months, ranging 0.1 to 20.3 months. Concurrent systemic therapy was used in 34 (81%), including 23 (55%) treated with immunotherapy. Objective response based on RANO was noted in 25/42 (60%) with interval response assessment. Only 2 (5%) experienced skin toxicity requiring interruptions. Progression free survival was 4.1 months, with a trend towards improved PFS with immunotherapy compared to other concomitant therapy (7.3 vs. 3.5 months, p=0.0997). Analyses of overall survival since start of TTF relative to concurrent immunotherapy use were limited by sample size and yet undefined median for the immunotherapy subgroup. Multivariable analyses, especially for the glioblastoma subgroup, will assess the potential benefit of combination TTF and immunotherapy adjusted for confounders. TTF improves survival for patients with glioblastomas. Immunotherapy shows promise for various tumor histologies. The possible synergism between these modalities in preclinical studies and this retrospective series warrants further study in randomized controlled glioma trials.
NCOG-06. USABILITY AND VALIDITY OF A PHONE BATTERY TO ASSESS LANGUAGE FUNCTIONS IN BRAIN TUMOR PATIENTS UNDERGOING AWAKE SURGERY
Authors: Elke De Witte, Vitoria Piai, Nina Dronkers, Mitchel S. Berger
Journal: Neuro-Oncology (2016)

Awake surgery in eloquent brain regions is performed to preserve language functions. Although in general no major permanent language deficits are found after awake brain surgery, clinically relevant impairments are detected (Satoer et al., 2014). Unfortunately, follow-up of tumor patients in the San Francisco area is difficult since most patients are not local and come from far. Therefore, we developed a short language phone battery for pre- and postoperative language assessments. Phase 1: task and item selection of the phone battery. The development of the phone battery was based on the Dutch Linguistic Intraoperative Protocol (De Witte et al., 2015) and existing standardized English batteries. Two parallel versions were composed and tested in healthy native English speakers. The test items were controlled for linguistic variables (e.g. frequency). Phase 2: clinical use of the phone battery in tumor patients. The phone battery was administered in a group of 15 tumor patients before surgery and at 1 week after surgery. Follow-up test moments at 1 month and 3 months postsurgery are planned. These patient data will be compared with language data collected in a group of 15 matched controls. Phase 1: The phone test battery includes auditory comprehension, repetition, semantic selection, sentence/story completion, verbal naming and fluency tests. It takes less than 20 minutes to administer. The healthy participants had no difficulty performing any of the seven language tests via the phone, attesting to the feasibility of a phone assessment. Phase 2: In the tumor group wordfinding, phonological and fluency problems were found at 1 week postsurgery. Longer follow-up data will be analysed and discussed. The use of telephone batteries to conduct language assessments from afar can provide convenience, reduce costs (for traveling), and optimize patient care as assessment services might be unavailable locally.
203P Molecular analysis of predictive biomarkers-KRAS, BRAF, NRAS and PIK3CA in colon cancer and correlation of clinico- pathological features with mutation profiling and therapeutic response in Indian patient cohort
Authors: H.A. Patil, S. Gada Saxena, C. Barrow, R.K. Kanwar, J.R. Kanwar, A. Kapat
Journal: Annals of Oncology (2016)
Innovation of multidisciplinary oncologic team through the workshops in rural area. -The challenge of MAHOLOBA-juku-
Authors: Masatoshi Kanno, Yusaku Akashi, Teruhisa Azuna, Yukio Aomatsu, Sayo Kotani, Shinya Kobayashi, Hiroshi Koyama, Hiroyuki Nakayama, Takehiro Yasuda, Yukishige Yamada
Journal: Annals of Oncology (2016)
Molecular Analysis of Immunoglobulin Variable Genes in HIV-Related Non-Hodgkin Lymphoma: Implications for Disease Pathogenesis and Histogenesis.
Authors: Daniela Capello, Eva Berra, Michaela Cerri, Annunziata Gloghini, Davide Rossi, Luigi M. Larocca, Antonino Carbone, Gianluca Gaidano
Journal: Blood (2005)
ZAP-70 Expression in Chronic Lymphocytic Leukemia (CLL) Is Independent of Rai Stage: A Retrospective Review of 38 Patients (pts).
Authors: Blanche H. Mavromatis, Bruce D. Cheson, Nicole D. Zantek, Dan-Paul Hartmann, Craig Kessler, Philip Cohen, Edmund Gehan, Metin Ozdemirli
Journal: Blood (2004)
A pilot study of neoadjuvant chemotherapy with gemcitabine (GMZ) plus a platinum compound in locally advanced bladder cancer: Preliminary results.
Authors: G. Nazzicone, G. Schinzari, M. Racioppi, A. Inno, A. Amoruso, A. Orlandi, D. Signorelli, V. A. Marsico, E. Cerchiaro, M. Quirino, P. F. Bassi, C. Barone
Journal: Journal of Clinical Oncology (2011)

e15142 Background: Radical cystectomy is commonly considered the standard primary approach for muscle-invasive bladder cancer (MIBC). Some randomized trials and a large metanalysis suggest an overall survival (OS) improvement in patients (pts) treated with a neoadjuvant cisplatin (CDDP)-based chemotherapy, even if the optimal regimen has not yet been identified; in several studies, pathological response rate was an independent prognostic factor for OS. Few data are available for the combination of GMZ with platinum compounds. We report our preliminary experience with neoadjuvant GMZ plus carboplatin (CBDCA) or CDDP in MIBC. Methods: Twenty pts (54-79 yrs, median age 76) satisfied inclusion criteria (age > 18 years, PS (ECOG) 0-1, histologically confirmed MIBC, stage ≥T2, no previous radiotherapy or chemotherapy) and received 3 cycles of GMZ (1000-1250 mg/m2, d. 1, 8) plus CBDCA (AUC 5, d. 1) or CDDP (75 mg/m2, d. 1) every 3 weeks, before undergoing radical cystectomy. Results: Fifteen out of 20 included patients have completed the planned course of chemotherapy and underwent radical cystectomy. Clinical overall response rate was 73% and no patient progressed during the treatment. 3 pts (21%) achieved a pathological complete response (pT0) and 4 pts (26%) a pathological partial response (pT1, pTis). Hematological (12% grade 3-4, 40% grade 1-2) and non-hematological (0% grade 3-4, 12% grade 1-2) toxicity was generally mild and easily manageable. Updated data will be presented at the meeting. Conclusions: These preliminary results from our pilot study suggest that GMZ plus a platinum compound as neoadjuvant chemotherapy may be a safe and effective approach for the treatment of MIBC, even in elderly pts.
RARE-35. PATIENT CHARACTERISTICS, PATTERNS OF CARE AND SURVIVAL OUTCOME IN PATIENTS WITH PEDIATRIC EXTRA VENTRICULAR NEUROCYTOMA: AN INDIVIDUAL PATIENT DATA ANALYSIS
Authors: Rony Benson, Supriya Mallick, Wineeta Melgandi, Goura Kishor Rath
Journal: Neuro-Oncology (2016)

Pediatric Extra Ventricular Neurocytoma (EVN) is extremely rare with less than 70 cases reported so far in literature. We performed PubMed search with the following MesH term: “neurocytoma extra ventricular” to find all possible publications pertaining to extra ventricular neurocytoma’s. Individual patient data on “tumor location, gender, type of surgery, radiation use, and survival” were tabulated in patients less than 18 years of age at presentation. Data was analyzed with SPSS version 16. A total of 60 cases (age less than 18 years) were found eligible for the analysis. Median age at diagnosis was 10.5 years (range: 0.6-18 years). The male: female ratio was 1.15:1. Imaging revealed calcification in 15 % of the cases. 76.6% of the patients had primary disease in supra tentorial area, while 13.3% had primary in the posterior fossa and 10% of the patients had tumor in the spinal cord. 56.6% underwent a gross or near total resection while 39.1% underwent a subtotal resection and 4.3% underwent a biopsy only. Median MIB labeling index was 4.5 (range: 1-40). Radiation was used in 13.3% of the patients while chemotherapy was used in only 1.6 % of the patients. Median follow up was 18 months (Range 1-192). The median progression free survival (PFS) was 15 years. Univariate analysis did not reveal gender, type of surgery, or use of adjuvant radiation to be significant factors affecting survival. Pediatric EVN is a very rare tumor. Most common site of tumor is supra tentotial. The patients are generally treated with surgery alone. The outcome in these patients is very good with a median PFS of 15 years.
Preventing chemotherapy-induced alopecia by scalp cooling: preliminary data from a study on the efficacy and safety of dignicap® system in breast cancer patients
Authors: G.M. Campennì, E. Munzone, N. Bianco, E. Montagna, P. Antonella, G. Cancello, A. Cardillo, M. Mazza, M. Iorfida, L. Rinaldi, G. Sortino, A. Scindivasci, C.C. Gornati, A. Elia, M. Colleoni
Journal: Annals of Oncology (2016)
Indirect Comparison of the Efficacy of Melphalan-Prednisone-Bortezomib Relative to Melphalan-Prednisone-Thalidomide and Melphalan-Prednisone for the First Line Treatment of Multiple Myeloma
Authors: Yating Yeh, James Chambers, Sabine Gaugris, Jeroen Jansen
Journal: Blood (2008)
Comparison of Airborne Mold in the Mojave Desert and Las Vegas
Authors: Tanviben Patel, Alyssa Panning, David Rivas, Hongbin Jin, Mark Buttner, Dennis Bazylinski, Joram S. Seggev
Journal: Journal of Allergy and Clinical Immunology (2017)

This study compared airborne mold concentrations in Las Vegas with the surrounding desert to determine seasonal variability between the urban and rural desert environments. Air samples were collected using a Burkard spore trap from January 1st to December 31st 2015, at a National Allergy Bureau (NAB) site in Las Vegas and a site in the Mojave Desert, located approximately 32 miles south of Las Vegas. Microscope slides were prepared and analyzed by light microscopy. Las Vegas had an annual mean of 374±280 spores/m3 compared to 350±265 spores/m3 at the Mojave site (p<0.01). The peak concentrations occurred in June (1917 spores/m3) in Las Vegas and in March (1789 spores/m3) for the Mojave site. There were differences observed between Cladosporium and smut concentrations. At the Mojave site, the peak was in July with 1151 spores/m3, while the peak was in June for Las Vegas (696 spores/m3). The smut concentrations for both sites had the highest concentrations in June, with lower concentration is Las Vegas (599 grains/m3) compared to the Mojave desert (1439 grains/m3). Mold concentrations in Las Vegas and the Mojave Desert show similar overall patterns. For both locations, Cladosporium and smuts had higher counts during the warmer months (March-September), which is consistent with expected trends for airborne molds. Although the Mojave location had a slightly lower mean concentration than Las Vegas, both Cladosporium and smut levels were higher in the Mojave site. Higher variation in the types of molds was observed at the Las Vegas site.
HLA-DR Protein Status Predicts Survival in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with the MACOP-B Chemotherapy Regimen.
Authors: Lisa M. Rimsza, Pedro Farinha, Deborah A. Fuchs, Hamid Masoudi, Joseph M. Connors, Randy D. Gascoyne
Journal: Blood (2004)
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients: an international multicentre hospital-based retrospective cohort study
Authors: M. Lambertini, A.C. Pinto, L. Ameye, L. Jongen, L. Del Mastro, F. Puglisi, F. Poggio, M. Bonotto, G. Floris, K. van Asten, H. Wildiers, P. Neven, E. de Azambuja, M. Paesmans, H.A. Azim
Journal: Annals of Oncology (2016)
Histone H3 Methylation Mediates All-Trans-Retinoic Acid Responsiveness in Acute Myeloid Leukemia
Authors: Tino Schenk, Stefanie Göllner, Weihsu Claire Chen, Louise Howell, Liqing Jin, Katja Hebestreit, Hans-Ulrich Klein, Alan K Burnett, Ken I. Mills, Laurence Marton, Robert Casero, Patrick Woster, Martin Dugas, Jean C.Y. Wang, John E. Dick, Carsten Müller-Tidow, Kevin Petrie, Arthur Zelent
Journal: Blood (2011)
Hypersensitivity Reactions to Nsaids in Children.
Authors: Natalia Blanca-Lopez, Diana Pérez-Alzate, Jose Antonio Cornejo, Natalia I. Perez-Sanchez, Maria Luisa Somoza, Francisco Javier Ruano, Elisa Haroun, Miguel Blanca, Gabriela Canto
Journal: Journal of Allergy and Clinical Immunology (2017)
Outcome of 583 Entry Double-Blind Placebo-Controlled Peanut Challenges during Screening for the Palisade Phase 3 Oral Immunotherapy Trial
Authors: Brian P. Vickery, Kirsten Beyer, A. Wesley Burks, Thomas B. Casale, Jonathan O. Hourihane, Stacie M. Jones, Amr Radwan, Andrea Vereda, Daniel C. Adelman
Journal: Journal of Allergy and Clinical Immunology (2017)
Immunophenotypic Analysis of Waldenstrom’s Macroglobulinemia: A Study of 63 Cases.
Authors: Andrea Toma, Magali Le Garff-Tavernier, Martine Brissard, Patrick Bonnemye, Lucile Musset, Nabih Azar, Veronique Leblond, Helene Merle-Beral
Journal: Blood (2007)
Allogeneic Stem Cell Transplantation for Hodgkin's Disease From Sibling and Unrelated Donors: The German Cooperative Transplantation Study Group Experience.
Authors: Christof Scheid, Peter Dreger, Dietrich W. Beelen, Martin Bornhäuser, Matthias Stelljes, Nikolaus Kröger, Max Topp, Gernot Stuhler, Ralf G Meyer, Wolfgang Andreas Bethge, Jörg Schubert, Rainer Schwerdtfeger, Igor W. Blau, William Hermann Krüger, Lutz Uharek, Michael Stadler, Hans Martin, Ralph Naumann, Peter Borchmann, Michael Hallek, Andreas Engert
Journal: Blood (2009)